LOS ANGELES, October 22, 2026--Puma Biotechnology will issue its third quarter 2026 results and host a conference call on Thursday, November 5, 2026, after the close.
On Thursday, Puma Biotechnology (NASDAQ:PBYI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
LOS ANGELES, October 05, 2026--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES, September 17, 2026--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
LOS ANGELES, September 09, 2026--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
LOS ANGELES, September 03, 2026--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
This is the newest page. Registered accounts read further back.